← Eichor
Study identifier: NCT06365788 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer

Condition: Triple Negative Breast Neoplasms  ·  Sponsor: Universitaire Ziekenhuizen KU Leuven

PhasePhase 2
Planned participants53
Who can joinFemale, 18 Years to no upper limit
Healthy volunteersNo

About this study

This study has as goal to evaluate the use of abemaciclib and bicalutamide in androgen receptor positive metastatic triple negative breast cancer.

This description comes directly from the study's public registry record.

Talk to the study team

Patrick Neven, MD, PhD  ·  +3216344750  ·  patrick.neven@uzleuven.be

Kristien Borremans, MD  ·  +321647795  ·  kristien.borremans@kuleuven.be

Always discuss trial participation with your own doctor first.

Locations (6)

ZAS AugustinusAntwerp, BelgiumRecruiting
Antwerp University HospitalAntwerp, BelgiumNot Yet Recruiting
University Hospital BrusselsBrussels, BelgiumRecruiting
Ghent University HospitalGhent, BelgiumRecruiting
Jessa ZiekenhuisHasselt, BelgiumRecruiting
University Hospitals LeuvenLeuven, BelgiumRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06365788